End points for clinical trials in acute heart failure syndromes.

Published

Journal Article (Review)

Acute heart failure syndromes (AHFS) remain a major cause of morbidity and mortality, in part because the development of new therapies for these disorders has been marked by frequent failure and little success. The heterogeneity of current approaches to AHFS drug development, particularly with regard to end points, remains a major potential barrier to progress in the field. End points involving hemodynamic status, biomarkers, symptoms, hospital stay, end organ function, and mortality have all been employed either alone or in combination in recent randomized clinical trials in AHFS. In this review, we will discuss the various end point domains from both a clinical and a statistical perspective, summarize the wide variety of end points used in completed and ongoing AHFS studies, and suggest steps for greater standardization of end points across AHFS trials.

Full Text

Duke Authors

Cited Authors

  • Allen, LA; Hernandez, AF; O'Connor, CM; Felker, GM

Published Date

  • June 16, 2009

Published In

Volume / Issue

  • 53 / 24

Start / End Page

  • 2248 - 2258

PubMed ID

  • 19520247

Pubmed Central ID

  • 19520247

Electronic International Standard Serial Number (EISSN)

  • 1558-3597

Digital Object Identifier (DOI)

  • 10.1016/j.jacc.2008.12.079

Language

  • eng

Conference Location

  • United States